TABLE 1.
Variables used for development of stepwise logistic regression models to predict death/BPD
| Category | Variable included for model development |
Variable description |
|---|---|---|
| Demographics | Birth weight | Birth weight (100g increments) |
| Gestation | Gestational age in completed weeks | |
| Gender | Gender | |
| Race | Race | |
| Outborn | Inborn vs. Outborn | |
| C-section | Mode of delivery | |
| Randomization age | Age at Randomization in hours | |
| Diagnosis | Primary diagnosis at randomization | |
| Illness severity | Mean FiO2 | Mean FiO2 at inclusion |
| Mean OI | Mean of inclusion OIs | |
| Response to iNO* | Treatment/Control | Allocation to treatment or control groups |
| PaO2 Diff 5 | Change in PaO2 Baseline to 5 ppm iNO | |
| PaO2 Max Diff | The greater of the change in PaO2 Baseline to 5 ppm and the change in PaO2 5 ppm to 10 ppm |
|
| Disease conditions prior to study initiation |
Air leak | Air leak (e.g. pneumothorax, interstitial emphysema) |
| GI Bleed | Gastrointestinal bleeding | |
| Oozing | Prolonged oozing of blood from iv sites | |
| Other bleeding | Other sites of bleeding | |
| Pulmonary hemorrhage | Clinically diagnosed pulmonary hemorrhage | |
| Seizures | Seizures | |
| Therapies prior to study initiation |
Ventilation mode | Mode of ventilation (conventional vs. high frequency) |
| Paralysis | Use of muscle relaxants | |
| Steroids | Use of postnatal steroids | |
| Surfactant dose | Surfactant doses administered | |
| Vasopressors | Vasopressor (e.g. dopamine, dobutamine) use | |
| Volume | Volume administration | |
| Sedation | Use of sedation/analgesia |
*
The treatment/control group allocation variable was used in the full data set analysis, and the response to iNO was used in analysis of the treatment group which received iNO.